GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » Other Current Liabilities

Implantica AG (OSTO:IMP A SDB) Other Current Liabilities : kr0.00 Mil (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Other Current Liabilities?

Implantica AG's other current liabilities for the quarter that ended in . 20 was kr0.00 Mil.

Implantica AG Other Current Liabilities Historical Data

The historical data trend for Implantica AG's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Other Current Liabilities Chart

Implantica AG Annual Data
Trend
Other Current Liabilities

Implantica AG Semi-Annual Data
Other Current Liabilities

Implantica AG Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Implantica AG Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Implantica AG's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Implantica AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » Other Current Liabilities
Comparable Companies
Traded in Other Exchanges
8IM1:Germany
Address
Aeulestrasse 45, Vaduz, LIE, 9490
Website
https://www.implantica.com
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines